PATENT CLAIM ANALYSIS

Application Number: 15997438
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["514", "262100"]

Abstract:
The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.

Claim (Index 42):
The method according to  claim 38 , wherein the PDE1 inhibitor is in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 94.0
- Lexical Diversity: 1.36667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13319807', '15263256', '12517945', '12514712', '13486264']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7919940739015748
- 35 USC 102 Novelty (BERT): 0.5731045850511144
- Combined Prediction Score: 0.7701051250165287
- Mean Citation Score: 418.093732
- Max Citation Score: 479.29242
- Similarity Product: 350.24057642224784

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test